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Computational machine learning-based frameworks could be extremely advantageous for neuropathologists to analyze pathologies in a scalable way. A
recent deep learning framework has shown promise in the ability to automate
the process of visualizing and quantifying different types of amyloid-beta
deposits as well as segmenting white matter (WM) from grey matter (GM) on
digitized immunohistochemically stained slides. However, this framework
has only been trained and evaluated on amyloid-beta-stained slides in one
neuroanatomic area (temporal cortex) scanned on select scanners. Evaluation
of the generalizability of this framework against heterogeneous slides especially with respect to pre-analytic variables remains limited. In the current pilot study, we evaluated select variables including multiple anatomic areas
(striatum, and frontal, and parietal cortices) and three digital slides scanners
(Zeiss Axioscan Z1, Leica Aperio AT2, and Leica Aperio GT 450), in addition to varying compression rates and magnifications using a cohort of 13
cases having a spectrum of amyloid-beta depositions. Statistical comparisons
of pre-analytic variables were conducted with Repeated Measures Analysis
of Variance. The framework performs consistently, with respect to varying
compression rates (40%, and 75%), compression standards (JPEG-XR and
JPEG-2000), and storage formats (svs, and czi) as there were no statistically
significant differences amongst amyloid-beta deposit measures (Ps >> 0.05).
Upon visual inspection of heatmaps, the framework has potential to perform
well across three cortical areas but not on the striatum given the differences
in tissue composition compared to the cortex. However, different scanners
and magnifications (5X, 20X, 40X) may impact the performance. This pilot
study highlights the significance of pre-analytic variables that may alter machine learning algorithms trained on a more limited dataset.
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Whole genome methylation profiling is proving to be an incredibly powerful
tool to diagnose tumors that are otherwise difficult to classify by histopathology and sequencing. The reference library of tumor DNA methylation data,
using a machine learning-based tumor classifier, was developed by the German Cancer Research Network (DKFZ), and is available publicly on a research basis. However, medical institutions desiring to implement that
classifier for routine clinical care need to import, adapt, and validate the classifier internally. We did this for our own DNA methylation-based classifier
of central nervous system (CNS) tumors, using the same training and validation datasets as the DKFZ group. In addition, we validated additional samples
from our own hospital, and compared the performance of both the original
DKFZ classifier and our internal modified classifier. Using the validation
data set, our classifier’s performance showed high concordance (92%) and
comparable accuracy (specificity 94.0% v. 84.9% 29 for DKFZ, sensitivity
88.6% v. 94.7% for DKFZ). Receiver operator curve showed areas under the
curve of 0.964 v. 0.966 for NM and DKFZ classifiers, respectively. Our classifier performed similarly well with samples tested in our own laboratory,
and is now being used on a routine clinical basis for CNS tumors. Herein, we
describe that process of importation, adaptation, and validation of the DKFZ
dataset, with the objective of providing a template by which other institutions
can do likewise.
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Introduction: Infiltrating cells in glioblastomas lead to recurrences after treatment and dismal prognosis. It is not clear which subpopulations of cells in
the tumor core acquire the ability to infiltrate or how they infiltrate. Many of
the infiltrating cells can be identified by light microscopy and immunohistochemistry. However, to investigate pathophysiologic mechanisms of infiltration, automated approaches are necessary to rapidly and accurately identify
all infiltrating glioblastoma cells in the infiltrating edge (IE) and the tumor
core (TC). In this project we designed and implemented a multistep machine
learning pipeline to segment the cells in TC and IE, calculate morphological
and textural features, and identify cells with similarities in TC and IE.
Methods: A set of 49 whole slide images (WSI) of glioblastomas (with adequate quality and pixel resolution) were randomly selected from The Cancer
Genome Atlas Program. Using QuPath software, representative TC and IE
areas were manually annotated. StarDist, a QuPath pre-trained deep-learning
extension, was used for nuclear segmentation. Performance of these segmented images were validated by pathologists’ evaluation. Morphological
and textural features (97 features per nucleus) were extracted from the segmented images for further analysis with the XGBoost classifier and visualization using t-SNE plots.
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Introduction: DNA methylation has emerged as a critical diagnostic tool in
neuropathology improving diagnostic accuracy. However, the utility in clinical practice is not well-defined for specific types of brain tumors. We provide
practical guidelines for considering DNA methylation in clinical practice.
Methods: We prospectively performed clinically validated NYS DOH approved whole genome DNA methylation profiling using Illumina EPIC array
and brain tumor classifier in a CLIA-certified lab on 1,298 primary brain
tumors. DNA methylation results were integrated with histopathology, immunochemistry, and problematic cases resolved using clinically validated
DNA and RNA next-generation sequencing for mutations, copy number aberrations and gene fusions. Traditional and DNA methylation diagnoses were
compared and classified as a complete match, partial mismatch, or complete
mismatch. A complete mismatch was defined as a change in histologic diagnosis or at least one WHO grade up or down. A partial mismatch was defined
as DNA methylation result contributing to further refinement or subclassification but not change in histopathology or WHO Grade.
Results: Analysis of the histology and DNA methylation showed that for descriptive diagnoses such as neuroepithelial tumor or glioneuronal tumor a definitive diagnosis was made by DNA methylation in 70% of cases while the
remaining 30% of cases were unclassifiable with a poor/no match by DNA
methylation. DNA methylation showed complete mismatch and change in diagnosis in tumors histologically diagnosed as PNET (63%), pineoblastoma
(27%), ependymoma (21%), astrocytoma (21%), oligodendroglioma (16%),
and low-grade glioma (14%). In other cases, the complete mismatch and
change in diagnosis was lower, including glioblastoma (8%), medulloblastoma (5%), meningioma (5%), and schwannoma (3%).
Conclusion: DNA methylation shows highest clinical value in descriptive
cases and embryonal tumors. Tumors histologically diagnosed as GBM, medulloblastoma, meningioma and schwannoma show low misdiagnosis rate by
DNA methylation profiling however molecular subclassification may be useful for prognosis.
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